Risk-adapted radiotherapy after breast-conserving surgery: Current standards and future developments, by @DavidKrugMD #bcsm karger.com/brc/article-abstr…
Angel Montero Luis retweeted
News from #ASTRO26: Real-world data indicate lower adherence rates for breast cancer endocrine therapy when radiation therapy is omitted
Nationwide insurance claims analysis finds fewer than 30% of patients remained adherent for five years after lumpectomy.
As seen in @Inside_PM, @AuntMinnie, HealthDay News, @cure_today & more. Presented by Shannon Jiang, MD.
Learn more: bit.ly/4ywQlUV
@WashUMedRadOnc @ShannonJiangMD
Angel Montero Luis retweeted
VIDEO: PMRT with breast reconstruction — 16 fractions instead of 25? RT CHARM (JCO, Oct 12, 2026): 24-mo reconstruction complications 12.3% vs 10.2%, noninferior ☢️🎗️
👉 oncologytube.com/pmrt-rt-cha…
🔹 Phase 3 Alliance A221505: 898 enrolled, 825 evaluable; 42.56 Gy/16 fx (~3 wk) vs 50 Gy/25 fx (5 wk)
🔹 Difference −2.1% (95% CI −6.5 to 2.2), within the 10% noninferiority margin; 36-mo LRR 1.5% vs 2.2%
🔹 Acute/late toxicity not different; implant-only reconstruction had more complications in both arms (OR 1.65)
Noninferior is not fewer complications: the 16-fraction rate was numerically higher, which belongs in the implant conversation.
@theRADSofKHAN @BHaffty @huntsmancancer @reshmajagsi @CShahMD @RTendulkarMD @ErinGillespieMD @RachelJimenezMD @KimCorbinMD @George_E_Naoum @shanestecklein @fumikochino @KHoffmanMD @NeilTaunkMD @DashaKlebaner @Sushilberiwal @5_utr @RadiantRehemaMD @JKocsisMD @drshuja3 @DrJudyBoughey @TariKingMD @kpmcguiremd @DrNimmiKapoor @DrSummerHanson @DrChrisHomsy @WilmotCancer @tmprowell @to_be_elizabeth @Monthy_A @MeritxellMolla @KefahMokbel @RICKLIN4TH @rrpaulinelli @drluismorenos
#bcsm #radonc #PMRT #breastcancer #breastreconstruction #hypofractionation
Angel Montero Luis retweeted
Dicen que cuando gobierne la ultraderecha retrocederemos 20 años:
Volveremos a los 1,8 Gy/fx? @Monthy_A
Angel Montero Luis retweeted
The “golden age of grift” may be coming to medicine.
Prediction markets are now being introduced to clinical trials, creating opportunities for insider trading, conflicts of interest, and manipulation of trial outcomes.
My new paper in @JCO_ASCO @ASCO: doi.org/10.1200/JCO-26-01303
pubmed.ncbi.nlm.nih.gov/4287…
@profgalloway @edels0n
Angel Montero Luis retweeted
News from #ASTRO26: Low-dose radiation therapy may slow progression of knee osteoarthritis, long-term study indicates
Randomized trial links treatment to sustained symptom relief, less joint deterioration and lower disability risk, with fewer knee replacements in patients with grade 2 disease.
As seen in @usnews, HealthDay News, @Medscape & more. Presented by Bobby (Nagendra) Koneru, MD, FASTRO.
Learn more: bit.ly/4s244kZ
@KoneruMd
Angel Montero Luis retweeted
Safety of combining #radiotherapy and antibody-drug conjugates in patients with #breastcancer: a systematic review and meta-analysis
@RO_GreenJournal @ESTRO_RT @OncoAlert
#OncoAlert #radonc #medonc
thegreenjournal.com/article/…
Angel Montero Luis retweeted
Amazing and timely keynote by Prof. @reshmajagsi on equity, culture, leadership and patient-centred care.
50 shades of disparity around the world 🌎
Closing session #FlorenceConsensus26
@OncoAlert @ESTRO_RT #OncoAlert #Oncology
De-escalation in breast cancer treatement is not a binary decision but a process of excellence in medicine: reduction without retreat, adaptation without surrender, precision without compromise #radonc #bcsm jmedradonc.org/de-escalating…
SABR-VMAT radiation therapy for recurrent cardiac sarcoma #radonc jmedradonc.org/when-surgery-…
De-escalating Breast Radiotherapy in the Age of Omission: No Retreat, Baby, No Surrender #radonc #bcsm jmedradonc.org/de-escalating…
Angel Montero Luis retweeted
Ya, Sr. @sanchezcastejon, pero usted es Presidente del Gobierno de un país que no reconoce la especialidad de enfermedades infecciosas.
nejm.org/doi/full/10.1056/NE…
Angel Montero Luis retweeted
Esto es verdaderamente vergonzoso
In a new Perspective, Pedro Sánchez (@sanchezcastejon), prime minister of Spain, and Tedros Adhanom Ghebreyesus (@DrTedros), director-general of the @WHO, reflect on the management of Andes hantavirus and the way in which careful, coordinated outbreak response can limit risk without undermining dignity. Read the full Perspective: nej.md/4hH61hM

ALT A quote from a Perspective published in the New England Journal of Medicine reads as follows: "Early diagnosis, isolation, clinical care, contact tracing, quarantine, close monitoring, and communication are more effective when people understand what is being asked of them and why." The Perspective is titled "Hantavirus — Lessons Learned about Security and Solidarity" and the authors are Pedro Sánchez and Tedros Adhanom Ghebreyesus. The text is displayed on a simple white background with a blue border. The NEJM identity sits at the bottom.
Angel Montero Luis retweeted
mm pattern 4 on biopsy far superior predictor of prostate cancer outcome than stage, grade, PSA, cores. We show using mm criteria rather than "favorable intermediate risk" would increase the number of US men eligible for active surveillance by >50,000. bjui-journals.onlinelibrary.…
Angel Montero Luis retweeted
Triste legado.
"Nadie nos puede echar en cara no haberlo intentado"
elmundo.es/salud/2026/10/06/…
Angel Montero Luis retweeted
🚨Registration closes on the 1st of November!! Will you miss the SABR all stars of #radiotherapy? Explore the Keynote talks here; sabrsymposium.com/keynote-ta… and don’t miss out 🇦🇺🦘🐨 #radonc
Angel Montero Luis retweeted
Thrilled to share that the The American Radium Society (ARS) Benign Committee has just published our new Appropriate Use Criteria (AUC) on Low-Dose Radiotherapy for the Treatment of Inflammatory Periarticular Disorders, covering conditions such as plantar fasciitis, shoulder tendinopathy, and greater trochanteric pain syndrome.
As Vice Chairman of the committee, I am incredibly proud of the dedication, quality, and momentum our team has maintained over the past six months.
A special thank you to Suzanne Russo and Austin Dove for their exceptional leadership throughout this initiative, and huge congratulations to Austin Kirschner, MD, PhD for leading this particular publication to completion!
Three-dimensional treatment planning and target volume definition of tendinitis and bursitis - Consensus statement of the International Benign Target Volume Group (IBTVG) #radonc #ldrt
Full paper: kwnsfk27.r.eu-west-1.awstrac…
Angel Montero Luis retweeted
🇯🇵 Provocative update from JCOG 0802 again shows that lobectomy is associated with inferior OS when stage I NSCLC is managed surgically. This time, among pts with high-risk pathological findings (LVI, VSI, pleural invasion, or LN metastasis). This rekindles the aphorism that wider surgical margins don't always = better outcomes, even though lobectomy improves RFS. jto.org/article/S1556-0864(2…


























